Astrana Health, Inc. (ASTH) — Fair Value Analysis

Base-case fair value (P50): $66.41 · Current price: $49.60 · Verdict: Undervalued

The Verdict on ASTH

Based on advanced Monte Carlo simulations, ASTRANA HEALTH INC (ASTH) appears undervalued at its current market price of $49.60. Our analysis, which models thousands of forward scenarios, indicates a median fair value (P50) of $66.41. This suggests a substantial +33.9% potential relative to its current trading level, presenting a compelling investment case for those seeking value within the healthcare space. The robust simulation framework consistently points to a disconnect between ASTH's intrinsic value and its present valuation.

How ASTH stacks up against peers

ASTRANA HEALTH INC currently maintains an average quality tier, reflecting a balanced operational and financial health compared to its sector peers. This average quality profile, combined with the significant +33.9% identified by our Monte Carlo analysis, positions ASTH as an interesting candidate. While not exhibiting top-tier operational metrics, its valuation discount from the $66.41 fair value of $66.41 provides an attractive entry point, particularly given the stock is trading at $49.60. The market seems to be overlooking the company's underlying value, despite its stable operational foundation.

What this means for investors

For investors, the current pricing of $49.60 relative to the median fair value of $66.41 signals a clear opportunity. The +33.9% potential, derived from our comprehensive Monte Carlo simulations, suggests that ASTH could deliver significant returns as its valuation converges towards its intrinsic worth. Given the company's average quality tier, this undervaluation provides an appealing risk-reward dynamic. To gain deeper insights into ASTH's full bear and bull case distribution and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.